Transforming Lives.
Transforming Lives

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

**Boston Scientific Products Treat 1:**

- **35 patients each minute**
- **52,000 each day**
- **365,000 each week**
- **19,000,000 each year**

Pictured above and on the cover are Laura and her family. Like so many other patients, her life has been transformed by a Boston Scientific product.

---

1  Numbers are rounded averages based on Company sales and estimated usage patterns as of December 31, 2013.

Throughout this Annual Report, unless otherwise noted, all revenue and growth rates represent 2013 growth compared to 2012 and all market sizes and Company market shares are Company estimates as of December 31, 2013.

Information on or connected to our website (or the website of any third party) referenced in this Annual Report is in addition to and not a part of or incorporated by reference into this Annual Report.
2013 Sales by Product Category

<table>
<thead>
<tr>
<th>Category</th>
<th>2013</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhythm Management</td>
<td>$1,886</td>
<td>27%</td>
</tr>
<tr>
<td>Cardiac Rhythm Management</td>
<td>$1,886</td>
<td>27%</td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>$155</td>
<td>2%</td>
</tr>
<tr>
<td>Cardiac Rhythm Management</td>
<td>$1,886</td>
<td>27%</td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>$155</td>
<td>2%</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>$1,997</td>
<td>28%</td>
</tr>
<tr>
<td>Interventional Cardiology</td>
<td>$1,997</td>
<td>28%</td>
</tr>
<tr>
<td>Peripheral Interventions</td>
<td>$789</td>
<td>11%</td>
</tr>
<tr>
<td>peripheral interventions</td>
<td>$789</td>
<td>11%</td>
</tr>
<tr>
<td>MedSurg</td>
<td>$453</td>
<td>6%</td>
</tr>
<tr>
<td>Neuromodulation</td>
<td>$453</td>
<td>6%</td>
</tr>
<tr>
<td>Endoscopy</td>
<td>$1,300</td>
<td>18%</td>
</tr>
<tr>
<td>Urology &amp; Women’s Health</td>
<td>$505</td>
<td>7%</td>
</tr>
<tr>
<td>Urology &amp; Women’s Health</td>
<td>$505</td>
<td>7%</td>
</tr>
<tr>
<td>Divested Businesses</td>
<td>$58</td>
<td>1%</td>
</tr>
<tr>
<td>Divested Businesses</td>
<td>$58</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$7,143</td>
<td>100%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$7,143</td>
<td>100%</td>
</tr>
</tbody>
</table>

2013 Sales by Geographic Segment

<table>
<thead>
<tr>
<th>Geographic Segment</th>
<th>2013</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>$3,743</td>
<td>52%</td>
</tr>
<tr>
<td>Japan</td>
<td>$744</td>
<td>10%</td>
</tr>
<tr>
<td>Other Countries</td>
<td>$2,598</td>
<td>37%</td>
</tr>
<tr>
<td>Other Countries</td>
<td>$2,598</td>
<td>37%</td>
</tr>
<tr>
<td>Divested Businesses</td>
<td>$58</td>
<td>1%</td>
</tr>
<tr>
<td>Divested Businesses</td>
<td>$58</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$7,143</td>
<td>100%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$7,143</td>
<td>100%</td>
</tr>
</tbody>
</table>

Increased Operational Net Sales³

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$7,127</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>$7,241</td>
<td>2%</td>
</tr>
</tbody>
</table>

Employee and country numbers are approximate.

---

2 Sales from divested businesses include those generated from the Company’s former Neurovascular business, sold to Stryker Corporation in January 2011.

3 Operational sales/revenue and growth rates are non-GAAP measures that exclude the impact of sales from divested businesses and changes in foreign currency exchange rates; see reconciliation to GAAP sales/revenue and growth rates on page 17.

Icon denotes additional information online at bostonscientific.com/2013ar
In 2013, we realized consolidated revenue of $7.143 billion. This represents a two percent increase in operational revenue and a one percent revenue decline on a reported basis. We delivered full-year adjusted earnings per share of $0.73. We improved gross profit margin to 69.6 percent from 67.6 percent in 2012—driven primarily from our standard cost reductions and process improvements. We continued to invest in meaningful innovation. Our Research & Development (R&D) expense was $861 million in 2013 or 12 percent of sales. We continued to pursue efficiencies in our R&D approach by leveraging innovation across the company. We deployed a balanced capital allocation strategy, which included repurchasing approximately $500 million of our common stock.

To improve our global effectiveness, we reorganized our business units in 2013 to operate and measure them from a global perspective along three reporting segments: MedSurg, which consists of our Neuro-modulation, Endoscopy, and Urology and Women’s Health businesses; Rhythm Management, which consists of our Cardiac Rhythm Management and Electrophysiology businesses; and Cardiovascular, which consists of our Interventional Cardiology and Peripheral Interventions businesses.

For 2013, the MedSurg segment grew revenue at nine percent on a constant currency basis and faster than its underlying markets, with each business performing well—led by growth of 24 percent in Neuromodulation, seven percent in Endoscopy, and three percent in Urology and Women’s Health. The Rhythm Management segment showed encouraging results with improved revenue in 2013. The sales within our Cardiovascular segment were down three percent on a constant currency basis in 2013, primarily due to softness in our sales of coronary drug-eluting stents (DES) offset, in part, by continued strength in our other cardiology products, such as guide wires and atherectomy devices.

Dear Stockholders:

In 2013, Boston Scientific continued our legacy of delivering meaningful innovation and executed on key financial and strategic goals. We are pleased with our performance and believe that we are well positioned to accelerate our growth and increase stockholder value.

In 2013, we delivered on our full year revenue and adjusted earnings growth goals and executed against our five strategic imperatives that include growing market share, expanding into high-growth adjacencies and global markets, driving margin improvements and developing talent and capabilities to lead in a dynamic global healthcare market. We believe that this execution helped to drive value for our stockholders.
Performance that Counts

We estimate that we grew faster than or at the market growth rate in five of seven of our businesses in 2013. Highlights of our 2013 performance:

• We continued to strengthen our market position in Neuromodulation, particularly in the U.S. where we estimate that the Precision Spectra™ Spinal Cord Stimulation (SCS) System took significant market share and accelerated overall market growth.

• In Endoscopy, our solid sales growth was driven primarily by our hemostasis franchise, biliary devices and metal stents. Our Alair® Bronchial Thermoplasty System, an innovative medical device for the treatment of severe asthma, delivered double-digit sales growth as we surpassed 350 treatment sites worldwide. Our Endoscopy business experienced strong international sales in 2013 as well, driven by expansion of our commercial capabilities, the registration of existing products, as well as continued investments in new products.

• In our Urology and Women’s Health business, sales in 2013 were driven by our global expansion and several new product launches. International sales strength in 2013 stemmed from registration of new products and a shift to a direct sales model in several European countries.

• Within our Cardiac Rhythm Management business, we estimate that we exited the year with sequential worldwide market share gains. Our pacemaker franchise continued to see strong adoption of our INGENIO® family of pacemaker systems. And in our defibrillation franchise there was broad physician interest in our S-ICD® System, the only subcutaneous implantable defibrillator available for the treatment of at-risk sudden cardiac death patients.

• The acquisition of C.R. Bard Inc.’s electrophysiology business enhanced our overall electrophysiology (EP) business by differentiating and expanding our commercial presence and product portfolio, including catheter and recording device technologies that will enable us to better serve the rapidly growing global EP market.

• Excluding DES, our Interventional Cardiology business delivered solid constant currency sales growth as we continued to offer physicians the broadest array of tools to treat the most complex lesions, from imaging catheters to atherectomy to devices designed to treat chronic total occlusions5.

• Peripheral Interventions demonstrated strong, consistent performance in 2013 by delivering above market constant currency growth, driven by our leading balloon and stent franchises6.

Innovation that Matters

Boston Scientific’s meaningful innovations are aimed at fueling our growth and meeting patient needs around the world. As the market shift toward value-based healthcare continues, customers, payers and patients are increasingly expecting solutions that deliver improvements in both clinical and economic outcomes. We see opportunities to meet the evolving needs of our changing market, to drive more value from our pipeline and to offer solutions that can ultimately transform the lives of more patients while enhancing overall value to the healthcare system.

A year ago, we introduced our new Company mission, six core values and brand declaration. Collectively, these words became our compass to guide us on our journey to return to growth. “Advancing science for life” now serves as our rallying cry, and our values of caring, diversity, winning spirit, meaningful innovation, global collaboration and high performance are a barometer against which we measure our actions.
We believe that our portfolio and pipeline are highly differentiated to meet both unique clinical value to patients and economic value to our customers. Key highlights in 2013:

- Our S-ICD® System won the prestigious 2013 Prix Galien USA Award for Best Medical Technology. This breakthrough technology is meaningful because it offers patients an alternative solution to transvenous ICDs, which require leads to be placed in the heart itself. We remain excited about this highly differentiated therapy and its unique ability to provide protection from sudden cardiac death without touching the heart.

- Our Alair® Bronchial Thermoplasty System was recognized as a finalist of the 2013 Prix Galien USA Award. For patients with drug-resistant asthma, this system helps to reduce asthma attack frequency and severity while potentially decreasing costly visits to the emergency room.

- We gained a favorable FDA Advisory Panel vote (13 to 1) for our WATCHMAN® Left Atrial Appendage Closure Device. This unique device is designed to close the left atrial appendage and prevent blood clot migration in atrial fibrillation patients, reducing the incidence of stroke and systemic embolism.

- We achieved CE Mark and FDA 510(k) clearance for our novel Rhythmia™ Mapping System designed to enhance treatment options and simplify complicated electrophysiology procedures.

- We received CE Mark approval for our Lotus™ Valve System, a next-generation transcatheter aortic valve replacement (TAVR) device that offers precise positioning and placement, with an outer skirt designed to limit paravalvular leak, a key determinant of long-term mortality.

- We enhanced our DES portfolio and capabilities with FDA approval and U.S. launch of our Promus PREMIER™ Coronary Stent System. This next-generation system offers physicians improved performance in treating patients with coronary artery disease. Internationally, our SYNERGY™ Coronary Stent System, a premium drug-eluting stent technology that features a bioabsorbable drug and polymer platform, continued to perform well.

- We strengthened our market position in the U.S. in 2013 with the Precision Spectra™ device, the world’s first and only SCS system with Illumina 3D™ Software and 32 contacts designed to provide chronic pain relief, with more coverage, flexibility and advanced control to a wider range of patients.

- We generated momentum with the Vessix™ Renal Denervation System, currently available in Europe, the Middle East, Australia, New Zealand and select markets in Asia. The Vessix System is a second-generation balloon-expandable, multipoint renal denervation platform that uses bipolar energy to disrupt the hyperactivity of renal sympathetic nerves that leads to uncontrolled high blood pressure.

Global Expansion

Expanding our global capabilities remains a strategic imperative to drive our growth. Our investments in the emerging markets are beginning to payoff. In 2013, our sales in Brazil, Russia, India and China (BRIC) grew on a constant currency basis by nearly 30 percent and in our total emerging markets by 20 percent. We believe that our realignment along global divisions has led to improved overall company performance, giving us the ability to better coordinate global product launches, balance our product portfolios and commercial resources and align investments in R&D with what we believe to be the high-return opportunities.

In 2013, we opened the Boston Scientific Institute for Advancing Science and the Innovation Center in Shanghai, China, and established an office for the first time in Russia. We believe these developments strengthen our ability to work closely with more customers around the world and bring new treatment options to the patients they serve.

---

5 Constant currency sales/revenue and growth rates are non-GAAP measures that exclude the impact of changes in foreign currency exchange rates; see reconciliation to GAAP sales/revenue and growth rates on page 17.

6 Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Advancing Science for Life

Looking ahead, we remain focused on executing our strategic imperatives and expect to continue to improve our financial performance, expand our operating margin and accelerate full-year operational revenue and adjusted earnings growth. Our goal is to grow our core businesses faster than the market and to grow our adjusted operating income faster than sales. Along with a focus on enhanced profitability, we expect to continue to generate strong cash flow to support investments aligned with our strategic priorities.

Beyond our business performance, Boston Scientific continues to embrace its role as a good corporate citizen in the communities where we live and work. Whether it is through sustainable business practices or a day of regional volunteering, we are investing time, talent and resources to bring support and services to these communities. On the sidebar to the right are a few examples of our efforts to transform lives in our communities.

Our organization is driven to develop meaningful innovation and to collaborate with our customers to advance science with the ultimate objective of transforming lives. Our employees are fulfilling that mission every day by helping patients, customers and the communities where our employees live and work.

We thank our stockholders for their continued support of Boston Scientific. We thank our employees for their dedication, winning spirit and high performance. And we look forward to reporting on our future progress.

Sincerely,

Michael Mahoney
President and Chief Executive Officer

Pete Nicholas
Chairman of the Board
March 18, 2014
Business Overviews

Boston Scientific technologies address a broad range of health conditions through seven business units that are organized into three global reporting segments: MedSurg, Rhythm Management and Cardiovascular.
MedSurg

Endoscopy focuses on diagnosing and treating diseases of the digestive system, airways and lungs, such as malignant and benign tumors, gastrointestinal diseases and cancers, abscesses and pulmonary diseases. Solutions include balloons, stents, endoscopic retrograde cholangiopancreatography (ERCP)/cholangioscopy, biopsy and polypectomy, hemostasis, radiofrequency ablation and enteral feeding.

Neuromodulation offers microelectronic implantable technologies for managing chronic neuropathic pain and neurological diseases. Technologies include rechargeable spinal cord stimulators and deep brain stimulators.

Urology and Women’s Health provides solutions for treating urological and gynecological disorders, such as kidney and bladder stones, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding. Our solutions include stone retrieval and lithotripsy, holmium laser ablation of the prostate, mid-urethral slings, pelvic floor reconstruction, urethral bulking and endometrial ablation.

Rhythm Management

Cardiac Rhythm Management provides solutions designed to treat irregular heart rhythms and heart failure, and to protect against sudden cardiac death. Technologies include pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices and remote monitoring systems.

Electrophysiology (EP) provides technologies such as mapping catheters, radiofrequency energy and cryogenics for diagnosing and treating cardiac arrhythmias and heart rhythm disorders.

Cardiovascular

Interventional Cardiology technologies diagnose and treat coronary artery disease and other cardiovascular disorders. Our solutions include drug-eluting and bare-metal stents, catheters, balloons, guide wires, coronary atherectomy and coronary intravascular ultrasound.

Peripheral Interventions focuses on developing solutions for peripheral vascular disease, liver cancer, hemodialysis access management and hypertension. Technologies include peripheral stents, guide wires and balloons, crossing devices, peripheral embolization products and drainage catheters.
“My chronic back pain made being a mom almost impossible. Now with the Precision Spectra™ System, I am able to be the active and involved mom I used to be. I feel like I have gotten my life back.”

– Laura
A busy 36-year-old stay-at-home mother of two, Laura was always on the move. She started experiencing back pain that she thought would just go away. As it persisted, Laura tried a variety of treatments, including steroids, physical therapy and painkillers. As the pain worsened, Laura became increasingly dependent upon her husband and eldest daughter to care for their family. She found it difficult to accomplish simple, daily activities. Sometimes her pain was so severe she’d be unable to get up from bed. Raising her youngest daughter became physically and emotionally challenging, as she was unable to be the kind of mom she envisioned.

While in a waiting room during one of many visits to her specialist, Laura read about spinal cord stimulation (SCS) and the Boston Scientific Precision Spectra™ System, the world’s first and only SCS system with Illumina 3D™ Software and 32 contacts. This system is designed to provide pain relief to a wider range of patients who suffer from chronic pain with more coverage, flexibility and advanced control. She became excited about this potential treatment and asked her doctor if it was right for her. Ultimately, she received the Precision Spectra System and now Laura has returned to her normal, busy life. She’s resumed bike riding with her family—a simple pleasure she hasn’t enjoyed in seven years.
Collaborating globally extends our reach and advances science

Advancing science requires close collaboration with healthcare professionals (HCPs) by soliciting their feedback during the product development process or during the design and execution of a clinical trial. How we train physicians to use our technologies is equally important. Training is especially critical when new products and procedures are developed as alternatives to traditional therapies. For example, executing a comprehensive physician training program helps lead to positive outcomes for physicians who implant the WATCHMAN® Left Atrial Appendage (LAA) Closure Device and allows for more patients to have access to this innovative device designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Dr. Klein delivers peer-to-peer specialized training on the WATCHMAN Device at the Boston Scientific Institute for Advancing Science in Paris. As an expert user, he familiarizes other physicians with this unique implant procedure and how to achieve the best clinical outcomes for patients. This type of advanced training is essential for innovative Boston Scientific therapies to be made available in medical centers around the world.

WATCHMAN® Left Atrial Appendage Closure Device

7 Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
"I am pleased to be involved with the Boston Scientific Institute for Advancing Science because it offers effective, interactive training on new procedures that help advance the practice of medicine."

– Prof. Dr. med. Gunnar Klein
“We always knew the WallFlex stent was capable of helping more patients, but the efforts of a cross-functional team turned that potential into a reality.”

– Mark Wood, R&D Engineer
Performing at the highest level to help more patients

Collaborating to find new ways to treat more patients is what we do at Boston Scientific. A good example is the WallFlex™ Biliary RX Stent, a leading stent designed for the palliative treatment of malignant biliary strictures, commonly caused by pancreatic cancer. A team of employees representing Clinical, R&D, Regulatory and Marketing focused on expanding the WallFlex indications to include treatment of benign biliary strictures. Together, they evaluated physician feedback, tested the stent and utilized clinical data to obtain an expanded European indication for WallFlex to be used in the treatment of both benign biliary strictures and those produced by malignant tumors. The result: successful treatment of more patients with the potential to improve the patients’ experience, to reduce the number of procedures they require and to decrease the overall cost of care.
Creating value through meaningful innovation

The global marketplace for medical devices is experiencing an accelerated rate of change. While remaining on the forefront of research and development and technology is critical, Boston Scientific is thinking differently about innovation and how to make it more meaningful. We are fostering a company culture of innovation that is not only centered on new products and technologies, but also transforming new ideas into breakthrough services, solutions and commercial models that create value for patients, customers and employees.
Award-winning breakthrough technologies

At the core of our meaningful innovation is breakthrough technology that transforms lives. In our tireless pursuit of technologies that can benefit more patients, it is especially gratifying when we are recognized for our ingenuity. The S-ICD® System won the 2013 Prix Galien USA Award for Best Medical Technology. This international award recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The S-ICD System is the world’s first and only commercially available subcutaneous implantable defibrillator that treats patients at risk for sudden cardiac death without touching the heart. In addition, we are proud that our Alair® Bronchial Thermoplasty System, which provides a unique and effective therapy for patients with severe asthma, was recognized as an award finalist.

State-of-the-art innovation hubs

At Boston Scientific, we recognize that for meaningful innovation to be fully realized, healthcare professionals’ awareness of the latest innovative technologies and industry trends is necessary. To that end, we operate three state-of-the-art Innovation Centers globally that are designed to drive understanding of our innovative technologies. Each Innovation Center provides a valuable forum for exchanging information and allows us to collect customer feedback to aid in the development of new products and technologies. In addition, the Boston Scientific Institute for Advancing Science (IAS) operates in six locations worldwide, the latest opening in Shanghai in the fall of 2013. These state-of-the-art professional education facilities offer interactive, multidisciplinary product and procedure training programs and “in the lab” education. Nearly 3,500 HCPs visit our IAS facilities each year.
Board of Directors

Katharine T. Bartlett 2,3  
Director; A. Kenneth Pye  
Professor of Law,  
Duke University School of Law

Bruce L. Byrnes 1,3  
Director; Retired Vice Chairman of the Board,  
The Procter and Gamble Company

Nelda J. Connors 4,5  
Director; Founder, Chairwoman  
and Chief Executive Officer,  
Pine Grove Holdings, LLC

Kristina M. Johnson, Ph.D. 2,4  
Director; Chief Executive Officer,  
Enduring Hydro, LLC

Edward J. Ludwig  
Director; Former Chief Executive Officer,  
President and Chairman,  
Becton, Dickinson and Company

Michael F. Mahoney  
Director; President and  
Chief Executive Officer

Ernest Mario, Ph.D. 1,2  
Director; Executive Chairman,  
Capnia, Inc.

N.J. Nicholas, Jr. 4  
Director; Private Investor

Pete M. Nicholas  
Director; Chairman of the Board;  
Co-Founder

Uwe E. Reinhardt, Ph.D. 1,5  
Director; Professor of  
economics and Public Affairs,  
Princeton University

David J. Roux  
Director; Co-Founder and Senior Director,  
Silver Lake

John E. Sununu 1,5  
Director; Former U.S. Senator

Director Emeritus

John E. Abele  
Director Emeritus; Co-Founder

Information is accurate as of March 1, 2014.  
1 Member of the Audit Committee  
2 Member of the Executive  
Compensation and Human Resources Committee  
3 Member of the Nominating and Governance Committee  
4 Member of the Finance Committee  
5 Member of the Compliance and Quality Committee

Executive Officers

Kevin J. Ballinger  
Senior Vice President and President,  
Interventional Cardiology

Supratim Bose  
Executive Vice President and President,  
Asia-Pacific, Middle East and Africa (AMEA)

Daniel J. Brennan  
Executive Vice President and  
Chief Financial Officer

Wendy Carruthers  
Senior Vice President,  
Human Resources

Keith D. Dawkins, M.D.  
Executive Vice President and  
Global Chief Medical Officer

Joseph M. Fitzgerald  
Executive Vice President and President,  
Rhythm Management

Jean Fitterer Lance  
Senior Vice President and  
Chief Compliance Officer

Michael F. Mahoney  
President and Chief Executive Officer

Jeffrey B. Mirvis  
Senior Vice President and President,  
Peripheral Interventions

Maulik Nanavaty  
Senior Vice President and President,  
Neuromodulation

J. Michael Onuscheck  
Senior Vice President and President,  
Europe

Michael P. Phalen  
Executive Vice President and President,  
MedSurg

David A. Pierce  
Senior Vice President and President,  
Endoscopy

Karen Prange  
Senior Vice President and President,  
Urology and Women’s Health

Timothy A. Pratt  
Executive Vice President,  
Chief Administrative Officer,  
General Counsel and Secretary

Kenneth J. Pucel  
Executive Vice President,  
Global Operations,  
Quality and Technology

Stockholder Information

Stock Listing

Boston Scientific Corporation common stock is traded on the NYSE under the symbol “BSX.”

Transfer Agent

Inquiries concerning the transfer or exchange of shares, lost stock certificates, duplicate mailings, or changes of address should be directed to the Company’s Transfer Agent at:

Computershare Inc.  
P.O. Box 30170  
College Station, TX  77842-3170

Shareholder website:  
www.computershare.com/investor

Shareholder online inquiries:  
https://www-us.computershare.com/investor/contact

Independent Registered Public Accounting Firm

Ernst & Young LLP  
Boston, Massachusetts

Annual Meeting

The 2014 annual meeting of stockholders will take place on Tuesday, May 6, 2014, beginning at 11:00 a.m. Eastern Time at Boston Scientific’s Corporate Headquarters located at One Boston Scientific Place, Natick, MA 01760.

Other Information

Copies of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports are available free of charge on our website at www.bostonscientific.com. Our Corporate Governance Guidelines and our Code of Conduct — which applies to all our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer — are also available on our website.

Certifications of the Chief Executive Officer and Chief Financial Officer certifying the accuracy of the Company’s public disclosures have been filed with the Securities and Exchange Commission as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Copies of these reports are also available by directing requests to:  
Investor Relations  
Boston Scientific Corporation  
One Boston Scientific Place  
Natick, MA 01760-1537  
508-650-8555  
508-647-2200 (Facsimile)  
Investor_Relations@bsci.com
Stockholder Information (cont.)

Safe Harbor for Forward-Looking Statements
This Annual Report contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Forward-looking statements include, among other things, statements regarding our expected sales and adjusted earnings and cash flows; our financial performance; our business plans; our positioning for growth; our cost savings strategies and growth initiatives, including our emerging markets strategy and investments, and their impact on our businesses; future and completed acquisitions, investments, divestitures, alliances and collaborations and their impact on our businesses; our market estimates and changes in the market and our market share for our businesses; clinical trials including timing and results, the strength of and expectations for our current and future product portfolio, including the impact our products will have on our businesses and financial results, markets, patients and the healthcare system generally; product development and iterations; research and development efforts and investments; the strength of our technologies and pipeline; regulatory approvals; our sales and marketing strategy; and our sustainability initiatives. Factors that may cause actual results to differ materially from those contemplated by the statements in this Annual Report can be found in our Annual Report on Form 10-K for the year ended December 31, 2013, under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Non-GAAP Reconciliations

<table>
<thead>
<tr>
<th>Earnings Per Diluted Share</th>
<th>2013</th>
<th>GAAP net (loss) income per share</th>
<th>$(0.09)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-GAAP adjustments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodwill and other intangible asset impairment charges</td>
<td>0.35 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquisition- and divestiture-related net charges</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring-related charges</td>
<td>0.07 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Litigation-related charges</td>
<td>0.11 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debt extinguishment charges</td>
<td>0.03 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discrete tax items</td>
<td>(0.01) *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization expense</td>
<td>0.27 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjusted net income per share</td>
<td>0.73</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Assumes dilution of 19.5 million shares for the year ended December 31, 2013 for all or a portion of these non-GAAP adjustments.

2013 vs 2012 Revenue and Relative Changes

<table>
<thead>
<tr>
<th>(Dollars in millions)</th>
<th>Year Ended December 31, 2013</th>
<th>As Reported Currency Basis</th>
<th>Less: Impact of Foreign Currency</th>
<th>Constant Currency Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventional Cardiology (IC)</td>
<td>$1,997</td>
<td>$2,179</td>
<td>-8%</td>
<td>-3%</td>
</tr>
<tr>
<td>Peripheral Interventions</td>
<td>789</td>
<td>774</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2,786</td>
<td>2,953</td>
<td>-6%</td>
<td>-3%</td>
</tr>
<tr>
<td>Cardiac Rhythm Management</td>
<td>1,886</td>
<td>1,908</td>
<td>-1%</td>
<td>-1%</td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>155</td>
<td>147</td>
<td>5%</td>
<td>-1%</td>
</tr>
<tr>
<td>Rhythm Management</td>
<td>2,041</td>
<td>2,055</td>
<td>-1%</td>
<td>-1%</td>
</tr>
<tr>
<td>Endoscopy</td>
<td>1,300</td>
<td>1,252</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Urology and Women's Health</td>
<td>505</td>
<td>500</td>
<td>1%</td>
<td>-2%</td>
</tr>
<tr>
<td>Neuromodulation</td>
<td>453</td>
<td>367</td>
<td>23%</td>
<td>0%</td>
</tr>
<tr>
<td>MedSurg</td>
<td>2,258</td>
<td>2,119</td>
<td>7%</td>
<td>3%</td>
</tr>
<tr>
<td>Subtotal Core Businesses</td>
<td>7,085</td>
<td>7,127</td>
<td>-1%</td>
<td>-2%</td>
</tr>
<tr>
<td>Divested Businesses</td>
<td>58</td>
<td>122</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Worldwide Sales (GAAP)</td>
<td>$7,143</td>
<td>$7,249</td>
<td>-1%</td>
<td>-2%</td>
</tr>
<tr>
<td>BRIC (year-over-year relative change)</td>
<td>25%</td>
<td>2%</td>
<td>27%</td>
<td></td>
</tr>
<tr>
<td>Emerging Markets (year-over-year relative change)</td>
<td>17%</td>
<td>-3%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>IC Sales (year-over-year relative change)</td>
<td>-8%</td>
<td>-3%</td>
<td>-6%</td>
<td></td>
</tr>
<tr>
<td>DES Sales (year-over-year relative change)</td>
<td>(-13%)</td>
<td>(-2%)</td>
<td>(-10%)</td>
<td></td>
</tr>
<tr>
<td>IC Sales excluding DES Sales (year-over-year relative change)</td>
<td>-2%</td>
<td>-3%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Worldwide Sales (GAAP)</td>
<td>$7,143</td>
<td>$7,249</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Divested Businesses Sales</td>
<td>-58</td>
<td>-122</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign Currency Impact</td>
<td>156</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operational Sales</td>
<td>$7,241</td>
<td>$7,127</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Our Mission
Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

Our Brand Declaration
“Advancing science for life” reflects what we do for patients, physicians and healthcare systems globally.

Advancing:
We push the boundaries of today’s innovations that lead to tomorrow’s medical solutions.

science:
Our heritage of discovery drives our passion for transforming lives.

for life:
We are committed to helping patients live healthier, longer lives.